The University of Chicago Header Logo

Connection

Rita Nanda to Camptothecin

Back to Details
This is a "connection" page, showing publications Rita Nanda has written about Camptothecin.
Rita Nanda
Connection Strength
1.080
Camptothecin
  1. Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States. Breast Cancer Res Treat. 2024 Nov; 208(1):203-214.
    View in: PubMed
    Score: 0.862
  2. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat. 2014 Aug; 146(3):557-66.
    View in: PubMed
    Score: 0.108
  3. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.
    View in: PubMed
    Score: 0.055
  4. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.